DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Tanezumab is an investigational drug.
There have been 17 clinical trials for Tanezumab. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2016.
The most common disease conditions in clinical trials are Osteoarthritis, Osteoarthritis, Knee, and Low Back Pain. The leading clinical trial sponsors are Pfizer, Eli Lilly and Company, and Massachusetts General Hospital.
There are ten US patents protecting this investigational drug and one hundred and fifty-four international patents.
Recent Clinical Trials for Tanezumab
|Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis||Pfizer||Phase 2|
|Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis||Massachusetts General Hospital||Phase 2|
|Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies||Eli Lilly and Company||Phase 3|
Top disease conditions for Tanezumab
Top clinical trial sponsors for Tanezumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Tanezumab||Start Trial||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||Start Trial|
|Tanezumab||Start Trial||Compositions and methods for detecting protease activity in biological systems||CytomX Therapeutics, Inc. (South San Francisco, CA)||Start Trial|
|Tanezumab||Start Trial||Binding-triggered transcriptional switches and methods of use thereof||The Regents of the University of California (Oakland, CA)||Start Trial|
|Tanezumab||Start Trial||Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same||CytomX Therapeutics, Inc. (South San Francisco, CA)||Start Trial|
|Tanezumab||Start Trial||Cell culture medium||LA JOLLA BIOLOGICS, INC. (San Diego, CA)||Start Trial|
|Tanezumab||Start Trial||Curcuphenol compounds for increasing MHC-I expression||CAVA HEALTHCARE INC. (CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|